1. 309 Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest. (25th January 2023) Authors: Reich, Kristian; Simpson, Eric; Langley, Richard; Warren, Richard B; Costanzo, Antonio; Saeki, Hidehisa; Almgren, Peter; Gjerum, Le; Carlsson, Anna; Gooderham, Melinda; Pinter, Andreas; De Bruin Weller, Marjolein; Blauvelt, Andrew Journal: British journal of dermatology Issue: Volume 188(2023)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 322 Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2). (25th January 2023) Authors: Blauvelt, Andrew; Thyssen, Jacob P; Guttman-Yassky, Emma ; Bieber, Thomas; Carrascosa, Jose Manuel; Simpson, Eric; Rosmarin, David ; Elmaraghy, Hany; Meskimen, Eric; Natalie, Chitra R; Liu, Zhuqing; Xu, Chenjia; Pierce, Evangeline; Morgan-Cox, MaryAnn; Silverberg, Jonathan I Journal: British journal of dermatology Issue: Volume 188(2023)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents. Issue 3 (June 2021) Authors: Luger, Thomas; Amagai, Masayuki; Dreno, Brigitte; Dagnelie, Marie-Ange; Liao, Wilson; Kabashima, Kenji; Schikowski, Tamara; Proksch, Ehrhardt; Elias, Peter M.; Simon, Michel; Simpson, Eric; Grinich, Erin; Schmuth, Matthias Journal: Journal of dermatological science Issue: Volume 102:Issue 3(2021) Page Start: 142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long‐term efficacy and patient‐reported outcomes. Issue 12 (4th November 2022) Authors: Simpson, Eric; Armstrong, April; Boguniewicz, Mark; Chiesa Fuxench, Zelma C.; Feely, Meghan; Pierce, Evangeline; Sun, Luna; Chen, Yun‐Fei; Angle, Robinette; Silverberg, Jonathan I. Journal: Dermatologic therapy Issue: Volume 35:Issue 12(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Chronic Hand Eczema Guidelines From an Expert Panel of the International Eczema Council. Issue 5 (September 2021) Authors: Silverberg, Jonathan I.; Guttman-Yassky, Emma; Agner, Tove; Bissonnette, Robert; Cohen, David E.; Simpson, Eric; Wollenberg, Andreas; Thyssen, Jacob P. Journal: Dermatitis Issue: Volume 32:Issue 5(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: the Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS). (3rd July 2019) Authors: Foley, Catherine; Tundia, Namita; Simpson, Eric; Teixeira, Henrique D.; Litcher-Kelly, Leighann; Bodhani, Amit Journal: Current medical research and opinion Issue: Volume 35:Number 7(2019) Page Start: 1139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Dunfermline Through Time. (2012) Authors: Simpson, Eric; Robertson, George Record Type: Book Extent: 1 online resource (96 pages) View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Dupilumab-Associated Ocular Surface Disease: Clinical Characteristics, Treatment, and Follow-Up. Issue 5 (May 2021) Authors: Bohner, Austin; Topham, Christina; Strunck, Jennifer; Haynes, Dylan; Brazil, Molly; Clements, John; Simpson, Eric; Chamberlain, Winston Journal: Cornea Issue: Volume 40:Issue 5(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials. Issue 9 (September 2018) Authors: Tofte, Susan J.; Papp, Kim; Sadick, Neil; Bohnert, Krista; Simpson, Eric; Thaçi, Diamant; Bieber, Thomas; Blauvelt, Andrew; Sofen, Howard; Gooderham, Melinda; Chen, Zhen; Gadkari, Abhijit; Eckert, Laurent; Graham, Neil M. H.; Pirozzi, Gianluca; Ardeleanu, Marius Journal: Journal of the American Association of Nurse Practitioners Issue: Volume 30:Issue 9(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. (17th November 2022) Authors: Reich, Kristian; Simpson, Eric; Wollenberg, Andreas; Bissonnette, Robert; Abe, Masatoshi; Cardillo, Tracy; Janes, Jonathan; Sun, Luna; Chen, Sherry; Silverberg, Jonathan I Journal: British journal of dermatology Issue: Volume 188:Number 2(2023) Page Start: 208 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗